enGenes Press Releases

enGenes brings enhanced protein yield opportunities to EFIB Brussels


enGenes brings enhanced protein yield opportunities to EFIB Brussels


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

SEPTEMBER 16, 2019

Vienna, Austria: – Recombinant protein specialist enGenes Biotech GmbH (enGenes) will be a new presence at the upcoming European Forum for Industrial Biotechnology & the Bioeconomy (EFIB 2019) in Brussels.

enGenes will use its first appearance at the annual partnering event to present successful applications of its proprietary enGenes-X-press technology in boosting recombinant protein and DNA yields to the Industrial Biotech sector.

Industrial biotech contribution

“This is an excellent opportunity to share latest news on our exciting enGenes-X-press platform. It has shown big potential to increase yields of recombinant proteins, even of difficult to express ones. We will reach out to new clients, establish new business relationships and share knowledge with leading figures in the industrial biotech arena,” commented enGenes CEO and CSO, Dr. Juergen Mairhofer.

E.coli-based platform

The enGenes team will make full use of the EFIB networked partnering platform to set up a series of one-to-one meetings in Brussels with potential clients and stakeholders in the Industrial Biotech sector.

“We will have a particularly compelling offer for companies having a need for cost-effective production using our E. coli protein expression platform,” said Dr. Mairhofer.

Protein production partner

“We will be able to show them that we can provide a reliable partnership for development of cost-effective manufacturing processes using enGenes-X-press technology, helping clients and partners save money by developing cost-effective manufacturing processes for enzymes or other recombinant proteins” he noted.

“We are also relevant partners for research project, as we have shown with various successful participation in EU or nationally funded projects such as XPAND, synBIOCarb and currently Rafts4Biotech,” Dr. Mairhofer concluded.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About EFIB 2019

The annual European Forum for Industrial Biotechnology & the Bioeconomy (EFIB) has become one of Europe’s leading event for the bio-based economy.

The partnering forum brings together more than 500 delegates from some 30 countries and 280 business, policy and science organisations to discuss emerging trends in industrial biotechnology.

EFIB 2019 is a three-day event opening September 30 at The Square meeting center in Brussels.

More than 80 speakers will discuss current issues in various focused tracks, with numerous company and start-ups presenting innovations. A co-located exhibition showcases global brands, emerging innovators and academic poster presentations.

Organizer is Europa Bio with further information at: https://efibforum.com.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707-0
Email: juergen.mairhofer@engenes.cc

Resources

Click on enGenes at EFIB 2019 Brussels for other information.
Click on enGenes Biotech GmbH to contact the company directly.
Click on Rafts 4 Biotech for more on enGenes participation in EU-funded project.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


enGenes participates in SynBIOcarb initiative


enGenes participates in SynBIOcarb initiative


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

AUGUST 16, 2019

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) will be one of the innovative small to medium sized enterprises (SMEs) participating in the EU-funded SynBIOcarb program.

SynBIOcarb is the project name for the Marie Skłodowska-Curie Action (MSCA) Innovative Training Network (H2020-MSCA-ITN) that brings together 15 early stage researchers working in PhD projects to bring forward different aspects of the emerging field of Synthetic Glycobiology towards applications in diagnostics and targeted delivery.

Early stage research

This diverse team of chemists, structural biologists, biophysicists, cell biologists and protein engineers are all supported by the EU-funded European Training Network. The project brings together five leading academic and research organisations from the UK, France, Germany, Denmark, and Slovakia, as well as enGenes and three other companies also leading industrial innovation in glycoscience-, protein- and bio-engineering. All will benefit from having the ESRs on their research teams.

The ‘beneficiary’ organizations will provide the ESRs with advanced scientific training in enabling technologies that underpin the development and exploitation of glycoscience for diagnostics and targeted drug delivery.

“The practical scientific training we are giving these young researchers is complemented by a coordinated programme of industry-relevant transferable skills that will prepare them for future careers in the medical technologies sector,” commented enGenes CEO, Dr. Jürgen Mairhofer.

Production of recombinant lectins

Dr. Mairhofer will supervise ESR Project 15, studying ‘Process Development for the Production of Recombinant Lectins in Escherichia coli’. For this project, PhD researcher Natalia Danielewicz will work in the enGenes laboratories in Vienna to study bioprocess development for the scalable production of different lectins in E. coli. The project will harness the proprietary enGenes X-Press technology platform that allows decoupling of cell growth from recombinant protein synthesis by using an engineered Escherichia coli host cell chassis.

Within this project, Natalia will work with different lectins used within the consortium, developing model manufacturing processes from one liter to 20L working scales, characterizing host cell response to conceptualize strategies for host cell engineering and finally obtaining improved production strains based on enGenes-X-press.

“This is exciting work that will combine state-of-the-art molecular biology with bioprocess engineering,” said Natalia.

Innovation driver

Polish-born Ms. Danielewicz comes to enGenes Biotech from Belgium, where she was working at Cargill Inc. in Brussels after obtaining her MSc masters from Vrije Universiteit Brussel, following her BSc. Degree from Middlesex University in the UK.

“As with our recent collaboration with the Austrian Centre of Industrial Biotechnology on improving recombinant protein yields of plant glycosyltransferase expression, this participation emphasizes the degree to which enGenes Biotech has become a driver for innovation,” said Dr. Jürgen Mairhofer.

“We are now seen as a valued partner for transnational research programs working closely with leaders in advanced fields of research,” he added.

Following SynGlycTis

Most of the partners involved in SynBIOcarb were involved in a previous project SynGlycTis, which between 2014 and 2018 investigated new strategies to build and functionalize proto-cells and proto-tissues within synthetic glycobiology. Europe-wide project was funded under the first joint call of the ERASynBio Initiative. The SynBIOcarb project will exploit many of the methods developed by the SynGlycTis consortium.

“While enGenes Biotech is a new partner, our involvement definitely makes sense since we have the bioprocessing skills and the enGenes X-press host strain platform needed to produce difficult-to-express lectins in E.coli,” commented Dr. Mairhofer.

Pharma and industrial implications

“This is a project with far-reaching implications for pharmaceutical and industrial companies. In particular spin-offs involved in synthetic biology, recombinant protein research and drug-conjugates who are seeking higher quality and yields of carbohydrate-binding therapeutics in upstream and downstream coupled production,” said SynBIOcarb project coordinator Prof. Bruce Turnbull, Professor of Biomolecular Chemistry at University of Leeds.

“The project will explore strategies for the development, quality control and delivery of novel biopharmaceuticals, and new diagnostic methods for detection of cancer based on glycan profiling. The Early Stage Researchers will be trained in a broad range of disciplines including protein engineering and site-directed labelling, cell biology and analytical methods from microarrays.” said Prof. Turnbull.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About SynBIOcarb

The SynBIOcarb European Training Network brings together a diverse team of chemists, structural biologists, biophysicists, cell biologists and protein engineers already involved in pioneering the development of Synthetic Glycobiology with four SME companies that are leaders in industrial innovation in glycoscience and protein engineering.

The aim of the project is advance pharmaceutical and industrial applications for synthetic glycobiology while simultaneously providing 15 PhD level early stage researchers (ESRs) with advanced scientific training in the technologies that enable and underpin the development and exploitation of glycoscience for diagnostics and targeted drug delivery.

Each ESR will contribute to one or more of the four thematic Work Packages that have been designed to progress the state-of-the-art in Synthetic Glycobiology.

Practical scientific training given to the ESRs is complemented by a coordinated programme of industry-relevant transferable skills to prepare them for future careers in the medical technologies sector.

SynBIOcarb involves leading research institutions University of Freiburg, University of Leeds, France’s Centre for National Scientific Research, Austrian Centre of Industrial Biotechnology, University of Copenhagen and the Slovak Academy of Science’s Institute of Chemistry; as well as four advanced research-based companies; enGenes, GlycoDiag, GlycoSeLect and Elicityl.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 814029.

For further information, see: https://synbiocarb.science/.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707-0
Email: office@engenes.cc

Resources

Click on enGenes participates in SynBIOcarb initiative for more information.
Click on enGenes Biotech GmbH to contact the company directly.

EnGenes


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


enGenes shows enhanced X-press protein yields at RPP conference


enGenes shows enhanced X-press protein yields at RPP conference


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

APRIL 10, 2019

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) will show successful application of its proprietary enGenes-X-press technology in significantly improving recombinant protein yields on its return to the recombinant protein production conference RPP10 in Crete.

enGenes is a silver sponsor of the event and attended the previous meeting in Dubrovnik in 2017.

At this year’s meeting, enGenes will present a poster and an oral presentation.

Growth-decoupled recombinant protein production in E. coli

“The RPP meeting is the foremost forum in the field of recombinant protein production bringing together an international cast of leasing players from industry and academia,” commented enGenes Biotech CEO, Dr. Juergen Mairhofer, who will attend the meeting, along with enGenes’s employee Patrick Stargardt, currently working on his PhD thesis.

Patrick Stargardt will deliver an oral presentation on ‘Growth-decoupled recombinant protein production in Escherichia coli’ during the morning session on Day Two of the meeting, focusing on Cell Engineering for Recombinant Protein Production.

Science-driven

“Together, our presentations will showcase our latest achievements in developing our enGenes-X-press technology to deliver enhanced yields in recombinant protein production by fine tuning expression levels for example” said Mr. Stargardt.

“Our presence and sponsorship of this valuable meeting emphasize that, above all, we are a science-driven company,” he added.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes., including its proprietary enGenes-X-press E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About RPP10

The RPP conference is a biennial event that offers a comprehensive overview of current challenges and innovative solutions in recombinant protein production, focusing on the comparative physiology of microbial and higher eukaryotic platforms for protein production.

The 2019 RPP conference (RPP10) is a four-day event opening April 24 at the Creta Maris Hotel at Hersonissos near Heraklion.

The conference will build on the successes of previous meetings, which have attracted steadily increasing numbers of researchers from both academia and the bioprocessing industry. The meeting will address major areas and emerging trends in industrially relevant recombinant protein production, including host physiology under bioprocess conditions, cell engineering, industrial-scale processes and new-format or difficult to express proteins

The event is jointly organized by the European Federation of Biotechnology (EFB) Microbial Physiology Section in partnership with the Federation of European Microbiological Societies (FEMS). Further information at: http://www.efbiotechnology.org/RPP.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707-0
Email: office@engenes.cc

Resources

Click on enGenes at RPP10 Crete for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


enGenes and acib to prove efficient site-specific incorporation of non-canonical amino acids into proteins


enGenes and acib to prove efficient site-specific incorporation of non-canonical amino acids into proteins


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

MARCH 07, 2019

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) is undertaking a proof-of-concept project that applies its patented enGenes-X-press technology to the cost-effective site-directed incorporation of non-canonical amino acids into proteins.

enGenes will be working as part of the XPAND project in partnership with the Austrian Centre of Industrial Biotechnology (acib). The project is funded by the Austrian Research Agency (FFG).

Antibody mimetic protein

Already, the partners have successfully achieved site-directed incorporation of non-natural azido-lysin into the model protein GFP and a Her2-directed affibody, an antibody mimetic protein.

The XPAND partners will reach out to companies interested in bio-conjugation to develop this technology further.

Emerging applications

Labelling of proteins with non-canonical amino acids is key to a number of emerging applications, such as fusing proteins with different functionality to generate novel therapeutics or generating more effective antibody-drug-conjugates (ADCs).

“We are very excited about the potential of the enGenes-X-press platform for non-canonical protein labelling. Using the enGenes-X-press platform we see that the incorporation of non-canonical amino acids is more efficient using the enGenes-X-press technology and therefore manufacturing of labelled proteins becomes far more cost-effective,” commented XPAND project leader Dr. Birgit Wiltschi, who is the leader of the Synthetic Biology Group at acib GmbH.

Cutting-edge protein labeling

enGenes CEO Dr. Juergen Mairhofer added: “Our participation in the XPAND project reflects the broad applicability of our technology to different fields of use. Non-canonical amino acids are very expensive, we are talking about 100-500 € per gram. Therefore, improving their incorporation efficiency into recombinant proteins directly safes money and makes this approach for site-specific protein modification more affordable and brings it closer to market. In particular, we can offer site-directed incorporation of non-canonical amino acids by the expansion of the genetic code and thereby enable whole new classes of products, such as single-species protein-drug conjugates,” said Dr. Mairhofer.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides cutting-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes., including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About ACIB GmbH

The Austrian Centre of Industrial Biotechnology (acib GmbH) is an international Research Centre for Industrial Biotechnology. ACIB scientists harness natural mechanisms to replace traditional industrial methods with new, more economic and ecological technologies.

Currently, more than 250 acib researchers are engaged in some 170 research projects at sites in Austria (Vienna, Graz, Innsbruck, Tulln), in Germany (Hamburg, Heidelberg, Bielefeld), Italy (Pavia), Spain (Barcelona), Australia, New Zealand and Taiwan as part of an international network of more than 150 international universities and industry partners, including BASF, DSM, Sandoz, Boehringer Ingelheim RCV, Jungbunzlauer and Validogen.

acib is co-owned by the Universities of Innsbruck and Graz, Graz University of Technology, the University of Natural Resources and Life Sciences, Vienna and Joanneum Research.

The Competence Center is sponsored by BMVIT, BMWFW and the provinces of Styria, Tyrol, Lower Austria and Vienna as part of the COMET program (Austrian Competence Centres for Excellent Technologies) managed by FFG, the Austrian Research Agency.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707-0
Email: office@engenes.cc

Resources

Click on enGenes and acib non-canonical protein labelling for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


New research study demonstrates enGenes X-press glycosyltransferase yield advantages


New research study demonstrates enGenes X-press glycosyltransferase yield advantages


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

FEBRUARY 07, 2019

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) has welcomed a new scientific publication showing successful application of its proprietary enGenes-X-press technology in significantly improving recombinant protein yields of difficult-to-express plant glycosyltransferases.

It demonstrates five-fold increases in yields of glycosyltransferase when using the enGenes-X-press strain compared to a state-of-the-art strain BL21(DE3), with a doubling in enzyme quality.

Peer-reviewed study

The study ‘Decoupling of recombinant protein production from Escherichia coli cell growth enhances functional expression of plant Leloir glycosyltransferases’ has been published in the prestigious journal Biotechnology and Bioengineering (DOI:10.1002/bit.26934).

The study has been leaded by Prof. Bernd Nidetzky, Head of the Institute of Biotechnology and Biochemical Engineering at Technical University Graz and CSO of ACIB GmbH, with contributions from enGenes CEO Dr. Juergen Mairhofer, and three other TU Graz and ACIB GmbH researchers, Martin Lemmerer, Alexander Lepak and Karin Longus and enGenes long-time collaborator Assoc. Prof. Dr. Rainer Hahn, affiliated to the University of Natural Resources and Life Sciences Vienna (BOKU).

The study is the result of collaborative research funded by the Austrian Research Promotion Agency, the FFG.

Releasing Leloir glycosyltransferase applications

The research team focused on sugar nucleotide‐dependent (Leloir) glycosyltransferases from plants as important catalysts for the glycosylation of small molecules and natural products whose application for biocatalytic synthesis is limited by their low protein expression of under 10 mg per liter of culture in standard microbial hosts.

The research focused on two representative glycosyltransferases, sucrose synthase from soybean and UGT71A15 from apple. They found that a synthetic biology‐based strategy of decoupling the enzyme expression from cell growth, as achievable with enGenes proprietary X-press platform technology, was effective in enhancing their individual production yield of correctly folded, biologically active proteins by up to five times, with a doubling in combined yield.

12-fold active enzyme increase

The glycosyltransferase genes were encoded on conventional pET‐based expression plasmids that allowed T7 RNA polymerase‐driven inducible expression by isopropyl‐β‐D‐galactoside. Laboratory batch and scaled‐up (20 L) fed‐batch bioreactor cultivations demonstrated up to 12‐fold improvements in overall yield of active enzyme as the result of production under growth‐decoupled conditions.

In batch culture, sucrose synthase and UGT71A15 were obtained, respectively, at 115 U/g and 2.30 U/g cell dry weight, corresponding to ∼5% and ∼1% of total intracellular protein.

Fed‐batch production gave sucrose synthase in a yield of 2,300 U/L of culture (830 mg protein/L).

Recombinant glycosyltransferase production

“Analyzing the isolated glycosyltransferase, we were able to show that improvement in the enzyme production was due to 5.3‐fold enhancement in yield and 2.3‐fold increase in quality of the soluble sucrose synthase,” commented first author Dr. Martin Lemmerer.

“Enzyme preparation from decoupled production comprised an increased portion (61% compared with 26%) of the active sucrose synthase homo‐tetramer. In summary, therefore, we show that expression in growth‐arrested E. coli is promising for recombinant production of plant Leloir glycosyltransferases,” the article abstract concludes.

Dr. Mairhofer commented: “This is a significant milestone for enGenes X-press, demonstrating that our arguments for its advantages are not just marketing ones but can be demonstrated in rigorous peer-reviewed academic research.”

“It also shows that the technology can achieve remarkable results in the hands of others in gaining significant yield improvements compared to state-of-the-art expression host strains,” he added.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes., including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About ACIB GmbH

The Austrian Centre of Industrial Biotechnology (ACIB GmbH) is an international Research Centre for Industrial Biotechnology. ACIB scientists harness natural mechanisms to replace traditional industrial methods with new, more economic and ecological technologies.

Currently, more than 250 ACIB researchers are engaged in some 170 research projects at sites in Austria (Vienna, Graz, Innsbruck, Tulln), in Germany (Hamburg, Heidelberg, Bielefeld), Italy (Pavia),Spain (Barcelona), Australia, New Zealand and Taiwan as part of an international network of more than 150 international universities and industry partners, including BASF, DSM, Sandoz, Boehringer Ingelheim RCV, Jungbunzlauer and VTU Technology.

ACIB is co-owned by the Universities of Innsbruck and Graz, Graz University of Technology, the University of Natural Resources and Life Sciences, Vienna and Joanneum Research.

The ACIB Competence Center is sponsored by BMVIT, BMWFW and the provinces of Styria, Tyrol, Lower Austria and Vienna as part of the COMET (Austrian Competence Centres for Excellent Technologies) program managed by FFG, the Austrian Research Agency.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707-0
Email: office@engenes.cc

Resources

Click on enGenes X-press glycosyltransferase study for more information.
Click on enGenes Biotech GmbH to contact the company directly.
Click on Biotechnology and Bioengineering to view abstract


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


enGenes showcasing X-Press and R&D highlights and opportunities at BIO-Europe 2018


enGenes showcasing X-Press and R&D highlights and opportunities at BIO-Europe 2018


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

OCTOBER 23, 2018

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) is returning for a fourth successive year to Europe’s leading partnering event, BIO-Europe, to present its latest biotech technologies and opportunities.

The enGenes presence at the Bella Center in the Danish capital, Copenhagen, will be led by CEO Juergen Mairhofer. They will highlight their advanced protein production technologies and the company’s newly designed service portfolio, designed to provide a wide range of realistic options for companies looking to develop cost-effective manufacturing processes for recombinant proteins.

F&E collaborations

“We are delighted to be returning to BIO-Europe, a conference we have attended every year since 2014,” said Dr. Mairhofer.

“For enGenes, this event is one of the highlights of our year and an excellent platform for meeting existing and potential new clients, discussing new research & development (R&D) partnerships and collaboration opportunities to apply our leading-edge technologies for protein production and development,” he added.

Powerful production processes

enGenes-X-press™ technology enhances the power of protein expression and production with growth-decoupled protein production in Escherichia coli (E.coli), enabling rapid development of economic, scalable and efficient production processes.

enGenes also offers a modular service model focused on the expression of difficult-to-express proteins covering all specific demands along the line from gene to protein, from cloning and vector optimization through to final purification.

Cost-effective protein manufacturing

“In summary, we can provide very cost-effective manufacturing solutions with a dedicated team of experts used to solve our clients technical issues,” said Juergen Mairhofer.

“We are inviting any potential partners clients who wish to explore possible collaborations to get in touch with us via the partneringONE platform to arrange face-to-face discussions in Copenhagen,” he added.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes., including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About BIO-Europe 2018

The BIO-Europe® Conference is Europe’s largest partnering event serving the global biotechnology industry, providing life science companies with high caliber knowledge sharing and partnering opportunities.

The 24th BIO-Europe Conference is a three-day event opening November 5 at the Bella Center, Copenhagen.

BIO-Europe 2018 will attract more than 4,000 industry attendees from some 60 countries, representing more than 2,100 companies for three days of high level networking. Partnering is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.

BIO-Europe is organized by EBD Group and KNECT 365 with further information at: https://ebdgroup.knect365.com/bioeurope/about-bio-europe

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707-0
Email: office@engenes.cc

Resources

Click on enGenes at BIO-Europe 2018 for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


XPAND protein labeling collaboration unites enGenes with ACIB


XPAND protein labeling collaboration unites enGenes with ACIB


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

APRIL 19, 2018

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) has announced the formation of the XPAND collaboration with ACIB GmbH to develop site-specific incorporation of non-native amino acids into proteins.

The new technology will be based on the enGenes-X-press platform for growth-decoupled protein production in Escherichia coli (E.coli), with expansion of the genetic code.

The Austrian Research Promotion agency (FFG) will fund the XPAND project as a BRIDGE 1 project, to close the “funding gap” between basic and applied research.

Cutting edge technology

“We are very excited about this new project, which underlines that enGenes Biotech is working on the cutting edge of industry relevant innovation,” commented enGenes CEO Dr. Juergen Mairhofer.

“Site-specific labelling is currently very inefficient and alternative approaches are leading to product heterogeneity. Our new approach will be more cost effective with higher labelling efficiencies to promote site specific labeling or conjugation of payload that is so relevant to antibody fragment drug conjugates, for example,” added Dr. Birgit Wiltschi, ACIB’s Junior Group Leader Synthetic Biology, ACIB GmbH.

Cheaper site-specific protein labeling

The business case for the project lies in the expensiveness of non-native (non canonical) amino acids as additives. Using enGenes-X-press technology should allow the partners to save resources and reduce cost by ensuring that the precious non-native amino acids are solely targeted upon the specific protein of interest.

“We aim to offer biopharma companies, CMOs, vaccine manufacturers, industrial biotech companies and start-ups a technology that provides them with a more efficient approach for site-specific labelling of proteins,” said Dr. Mairhofer.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost effective recombinant protein production processes., including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About ACIB GmbH

The Austrian Centre of Industrial Biotechnology (acib) is an international Research Centre for Industrial Biotechnology with locations in Vienna, Graz, Innsbruck, Tulln, Vienna (A), Hamburg, Heidelberg, Bielefeld (D), Pavia (I) and Barcelona (E), Canterbury (AUS), New Zealand (NZL) and Taiwan. Using the concepts of nature, acib-scientists replace traditional industrial methods with new, more economic and ecological technologies.

Actually, acib is an international network of 150+ international universities and industry partners, including BASF, DSM, Sandoz, Boehringer Ingelheim RCV, Jungbunzlauer or VTU Technology. Owners are the Universities of Innsbruck and Graz, Graz University of Technology, the University of Natural Resources and Life Sciences, Vienna and Joanneum Research.

At acib 250+ scientific employees with up to 30+ years of experience in industrial biotechnology work in more than 170 research projects. The competence center acib is sponsored within COMET (Austrian Competence Centres for Excellent Technologies) by the BMVIT, BMWFW and the provinces of Styria, Tyrol, Lower Austria and Vienna. The COMET program is handled by the FFG.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707
Email: office@engenes.cc

Resources

Click on enGenes announces XPAND protein labeling collaboration for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


enGenes deploys X-press technology to modular prokaryotic protein expression services


enGenes deploys X-press technology to modular prokaryotic protein expression services


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

JANUARY 25, 2018

Vienna, Austria: – Recombinant protein specialist manufacturer and service provider enGenes Biotech GmbH (enGenes) has mobilized its proprietary X-press technology to support a new range of gene expression and prokaryotic protein production services.

The service portfolio is designed and structured on modular lines to provide a wide range of realistic options for companies looking to develop cost-effective manufacturing processes for recombinant proteins.

Step by step

The service model is focused on the expression of difficult-to-express proteins covering all specific demands along the line from gene to protein. It is divided into a series of steps that can be performed either individually or in combination – allowing customers to choose from a menu of the steps actually required, including:

  • Cloning and vector optimization
  • Generation of expression strain and host cell engineering
  • Feasibility studies for enGenes-X-press application
  • Lab scale fermentations and bioprocess optimization
  • Establishing purification protocol and final purification

X-press power

The protein expression and production elements are enhanced by the power of the world-leading enGenes-X-press technology for growth-decoupled protein production in Escherichia coli (E.coli). This has allowed enGenes to develop economic, scalable and efficient production processes within short time frames.

enGenes X-press has proven ability to achieve outstanding yields of soluble and active recombinant protein, radically improving on the existing T7 expression system. The technology is fully scaleable and can be operated at cell densities up to 100 g/L biomass, allowing high specific and volumetric yields. The production platform has already unlocked successful manufacture of enzymes and biopharmaceutical products that failed to give economically feasible yields in conventional expression hosts, such as BL21(DE3).

Optimized protein expression and bioprocess in E. coli

enGenes now offers a modular system of customer services for gene expression and protein production in Escherichia coli (E.coli) and other prokaryotes (e.g. Bacillus subtilis).

“Our world-leading enGenes-X-press™ technology for growth-decoupled protein production allows us to develop economic, scalable and efficient production processes within short time frames with the productivity power required to transform our customers’ unique products into commercial successes,” said enGenes Biotech CEO, Dr. Juergen Mairhofer.

enGenes recently announced a new collaboration with the Technical University of Vienna to apply the company’s proprietary enGenes-X-press™ technology to integrative bioprocess development for biosimilar production. The collaboration emphasizes enGenes’ strengths in Research & Development (R&D) and its vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press™ has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707
Email: office@engenes.cc

Resources

Click on enGenes prokaryotic protein expression for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


enGenes brings X-Press industrial biotech applications to ESIB


enGenes brings X-Press industrial biotech applications to ESIB


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

NOVEMBER 02, 2017

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) will makes its debut at the second ESIB industrial biotechnology summit in Graz, Austria, next month.

The enGenes team, led by CEO Juergen Mairhofer, will attend the event at the Messecongress Graz conference center to present the company’s latest technologies and the company’s newly designed service portfolio, designed and structured on modular lines.

The service offer provides a wide range of realistic options for companies looking to develop cost-effective manufacturing processes for recombinant proteins.

X-press application

Dr. Mairhofer will be accompanied at ESIB by enGenes staff scientist Lukas Feuchtenhofer, who will present a poster on “Using the enGenes-X-press platform for the production of value-added products in Escherichia coli”.

The enGenes team will also use one of the summit’s “Science Flash” sessions to present the power of enGenes-X-press for growth-decoupled protein production in E.coli. This has allowed enGenes to develop economic, scalable and efficient production processes within short time frames.

Cost-effective biotech production

“This is our first time at the ESIB summit. We noted with interest the very favorable reaction to last year’s initial summit and believe this event provides great opportunities to strengthen our partnerships within the industrial biotechnology community” said Dr. Mairhofer.

“We look forward to this opportunity to discuss exciting new opportunities to apply our enGenes-X-press technology to cost-effective manufacturing of bio-based products like enzymes or enzyme-derived chemicals,” he added.

“We invite anyone looking for flexible recombinant protein development and production solutions to contact us via ESIB’s Matchmaking Event so we can set up face-to-face meetings in Graz,” said Dr. Mairhofer.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About ESIB 2017

The European Summit of Industrial Biotechnology (ESIB) was founded in 2016 to provide a new European communication platform for industrial biotechnology, bringing together scientific topics with industrial needs and priorities, economic demands, funding resources and political aspirations in an event that combines knowledge-sharing, networking and recreation.

The second summit, ESIB 2017, is a three-day event opening November 14 at the Messecongress in the center of the ancient Austrian university city of Graz.

The event is organized by the Austrian Centre of Industrial Biotechnology (ACIB) with more information available at: https://esib.at/

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707
Email: office@engenes.cc

Resources

Click on enGenes at ESIB for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


enGenes brings X-Press technologies to BIO-Europe


enGenes brings X-Press technologies to BIO-Europe


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

OCTOBER 25, 2017

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) will present its latest technologies and service offers at the upcoming BIO-Europe biotechnology partnering conference.

enGenes Biotech, represented by by CEO Juergen Mairhofer, will attend the event at the City Cube Berlin Conference Center. enGenes will use the meeting to highlight their latest technologies and the company’s newly designed service portfolio, designed and structured on modular lines to provide a wide range of realistic options for companies looking to develop cost-effective manufacturing processes for recombinant proteins.

X-press applications

“We have attended every BIO-Europe conference since 2014 and find this is an excellent platform for widening and deepening our partnerships within the life sciences community,” said Dr. Mairhofer.

“We look forward to this opportunity to meet existing and potential new clients and to discuss exciting new opportunities to apply our enGenes-X-press technology to protein production and development,” he added.

The new enGenes service model is focused on the expression of difficult-to-express proteins covering all specific demands along the line from gene to protein., is divided into a series of steps that can be performed either individually or in combination – allowing customers to choose from a menu of the steps actually require, from cloning and vector optimization through to final purification.

Powerful production processes


The protein expression and production elements are enhanced by the power of the world-leading enGenes-X-press technology for growth-decoupled protein production in Escherichia coli (E.coli). This has allowed enGenes to develop economic, scalable and efficient production processes within short time frames.

“We are inviting anyone looking for flexible recombinant protein development and production solutions to contact us via BIO-Europe’s excellent partneringONE platform so we can set up face-to-face meetings in Berlin,” said Dr. Mairhofer.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About BIO-Europe 2017

The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.

BIO-Europe 2017 is a three-day event opening November 6 at Berlin’s City Cube conference center.

BIO-Europe has formed the launch pad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.

This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.

Partnering at BIO-Europe 2017 is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.

More information at: www.ebdgroup.knect365.com/bioeurope/

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707
Email: office@engenes.cc

Resources

Click on enGenes at BIO-Europe for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


New project applies enGenes X-press to biosimilars


New project applies enGenes X-press to biosimilars


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

AUGUST 17, 2017

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) has announced a new collaboration with the Technical University of Vienna (TU Wien) to apply the company’s proprietary enGenes-X-press™ technology to integrative bioprocess development for biosimilar production.

The project, funded by the Wiener Wirtschaftsagentur (Vienna Business Agency), has considerable implications for biosimilars companies, holding out the prospect of decreased manufacturing costs for complex molecules, reduced time-to-market and diminished development risks. The mid-term goal is to provide cell lines and manufacturing processes with certified quality parameters such as biological activity in bioassays or comparative biosimilarity to originator.

enGenes-X-press – a cutting edge bacterial production platform

Prospects for achieving these aims largely rest on the X-press E. coli platform’s proven ability to achieve outstanding yields of soluble and active recombinant protein, radically improving on the existing T7 expression system. The technology is fully scaleable and can be operated at high cell densities (up to 80-100 g/L biomass), allowing high specific and volumetric yields.

enGenes-X-press technology has already unlocked successful manufacture of enzymes and biopharmaceutical products that failed to give economically feasible yields in conventional expression hosts, such as BL21(DE3).

“We believe this project will be of great interest to biosimilar manufacturers looking for ways to create the cheapest possible characterization and development program to achieve price competitiveness in the market without losing valuable time,” said Asst. Prof. Dr. Oliver Spadiut, Head of the Research Group for Integrated Bioprocess Development at TU Wien.

enGenes R&D strengths

The collaboration emphasizes enGenes’ strengths in Research & Development (R&D) and its vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

“We are not only a company that is out licensing technology; we do a lot of research and we drive innovation to offer really the best technologies and services to our clients,” said enGenes Biotech CEO, Dr. Juergen Mairhofer.

“This project provides us with the opportunity to determine mechanistic correlations between fermentation parameters and final biosimilar quality. Knowing these correlations is of high value since this allows us to manufacture high quality molecules like antibody fragments with high yields in less time within a pre-defined quality target range and therefore allows to significantly decrease time-to-market,” said Dr. Mairhofer.

Focus on innovation

Driving innovation is a core business activity for enGenes, which is participating in several other projects supported by the Austrian Research Promotion Agency (FFG), or international funding bodies like the European Union.

The company is also part of the H2020 Rafts4Biotech project (www.rafts4biotech.eu), a project that builds upon the discovery of bacterial lipid rafts to exploit them as a biotechnological tool for spatial confinement of reactions of industrial interest.

“We work with the best people in the field and we are very open to collaborative projects,” said Dr. Mairhofer.

“We shape our activities in biosimilars to make ourselves ideal partners for people working in the field, being able to provide advanced process development to complement the work of companies with expertise in drug development and biosimilars, looking to produce those molecules with reasonable and economically feasible yields,” he added.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost effective recombinant protein production processes., including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707
Email: office@engenes.cc

Resources

Click on enGenes X-press applied to biosimilars for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc